Skip to main content
SpringerLink
Log in

Highlights of ASH 2019—multiple myeloma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The 2019 meeting of the American Society of Hematology (ASH) was dominated by new data from clinical research; effective combinations of mostly recently approved drugs and studies with new promising agents and treatment concepts, currently in the preapproval status, were on the forefront of attendee’s interest. Results from the ALCYONE study revealed a significant survival advantage with the addition of daratumumab, thus, highlighting the therapeutic potential of monoclonal antibodies. These antibodies are becoming standard combination partners for all lines of therapy. Presently, it remains unclear whether CAR‑T cells will win the race against immunoconjugates and other novel immunotherapies, or whether a combination of both will be used in the future, and not only at late relapse, but already as first-line therapy, particularly in high-risk disease. The large number of new drugs with new modes of activity will rescue an increasing number of patients with relapsed/refractory disease and, for sure, will move to earlier lines of therapy. ASH 2019 made it clear—the future is now.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Voorhees P, et al. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Griffin Study update. Blood. 2019;134:691.

    Article  Google Scholar 

  2. Costa L, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-Krd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134:860.

    Article  Google Scholar 

  3. Rifkin R, et al. Daratumumab (DARA) maintenance therapy improves depth of response and results in durable progression-free survival (PFS) following Dara plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): update of the Lyra Study. Blood. 2019;134:863.

    Article  Google Scholar 

  4. Mateos M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone. Blood. 2019;134:859.

    Article  Google Scholar 

  5. Vij R, et al. Ixazomib or lenalidomide maintenance following autologous stem cell transplantation and ixazomib, lenalidomide, and dexamethasone (IRD) consolidation in patients with newly diagnosed multiple myeloma: results from a large multi-center randomized phase II trial. Blood. 2019;134:602.

    Article  Google Scholar 

  6. Usmani S, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688). Blood. 2019;134:LBA‑6.

    Article  Google Scholar 

  7. Moreau P, et al. Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study. Blood. 2019;134:692.

    Article  Google Scholar 

  8. Terpos E, et al. Progression-free survival analysis of denosumab vs zoledronic acid in intent to transplant multiple myeloma patients based on treatment regimen and baseline characteristics. Blood. 2019;134:606.

    Article  Google Scholar 

  9. Krishnan A, et al. Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:140.

    Article  Google Scholar 

  10. Costa L, et al. First clinical study of the B‑cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143.

    Article  Google Scholar 

  11. Harrison S, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood. 2019;134:142.

    Article  Google Scholar 

  12. Chen C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:141.

    Article  Google Scholar 

  13. Cowan A, et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:204.

    Article  Google Scholar 

  14. Amatangelo M, et al. Multidimensional single cell analysis shows increased T/NK cell subsets in both blood and bone marrow of Iberdomide (CC-220) treated relapsed/refractory multiple myeloma patients. Blood. 2019;134:1775.

    Article  Google Scholar 

  15. Mateos M, et al. Clinical activity of Melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed/refractory multiple myeloma refractory to pomalidomide and/or daratumumab. Blood. 2019;134:1883.

    Article  Google Scholar 

  16. Ocio E, et al. ANCHOR (OP-104): updated efficacy and safety from a phase 1/2 study of melflufen and dexamethasone plus bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD or a proteasome inhibitor (PI). Blood. 2019;134:3124.

    Article  Google Scholar 

  17. Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21. https://doi.org/10.1016/S1470-2045(19)30788-0.

    Article  CAS  PubMed  Google Scholar 

  18. Weisel K, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom/Dex) in participants with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:1900.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wilhelminen Cancer Research Institute, Montleartstraße 37, 1160, Vienna, Austria

    Heinz Ludwig

Authors
  1. Heinz Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinz Ludwig.

Ethics declarations

Conflict of interest

H. Ludwig received research funding from Amgen and Takeda, and personal fees for advisory boards/speaker’s bureau from Amgen, Takeda, Celgene, Janssen, Sanofi, and Seattle Genetics.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ludwig, H. Highlights of ASH 2019—multiple myeloma. memo 13, 270–275 (2020). https://doi.org/10.1007/s12254-020-00612-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00612-1

Keywords

Search

Navigation